Clinical Trial Detail

NCT ID NCT03789110
Title NIMBUS: A Phase II Study of Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Dana-Farber Cancer Institute
Indications

Her2-receptor negative breast cancer

Therapies

Nivolumab + Ipilimumab

Age Groups: adult senior

Additional content available in CKB BOOST